The company has won in the Business Expansion category for its new business launch, and in the Research & Development category in the critical areas of breast cancer and neurology.

Business Expansion award for AstraZeneca

AstraZeneca launched Evinova, a health-tech business, marking a pivotal step in accelerating innovation across the life sciences sector and fostering business expansion. Evinova, operating as a separate entity within AstraZeneca, leverages globally-scaled digital health solutions that cater to a broad spectrum of stakeholders, including clinical trial sponsors, clinical research organisations (CROs), clinical trial site care teams, and patients.

Evinova’s strategic collaborations with leading CROs such as Parexel and Fortrea extend its digital health solutions to a vast customer base.

R&D awards for AstraZeneca

AstraZeneca has won two awards within the Research and Development category for the success of two of its products – one in oncology and the other in CNS therapy area.

The first product is Truqap (capivasertib), in combination with Faslodex (fulvestrant), which received US approval for the treatment of adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer with specific biomarker alterations. The approval is a testament to AstraZeneca’s commitment to addressing the urgent need for new treatment options in the breast cancer landscape.

The FDA’s approval of Truqap, a first-in-class AKT inhibitor, is based on the compelling results from the CAPItello-291 Phase III trial, which demonstrated a 50% reduction in the risk of disease progression or death compared to Faslodex alone in the biomarker-altered population. This groundbreaking combination offers a new treatment option for up to half of the patients with advanced HR-positive breast cancer, potentially delaying disease progression and providing more time with their disease under control.

The rapid US approval of Truqap underscores the importance of the PI3K/AKT pathway in HR-positive breast cancer and the critical need for biomarker testing at the time of diagnosis. With regulatory applications under review in various countries, AstraZeneca is poised to bring Truqap to breast cancer patients worldwide, furthering its ambition to eliminate breast cancer as a cause of death.

The second drug is Wainua (eplontersen), which was granted regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis. The approval is a significant milestone in the treatment of this debilitating disease, which leads to peripheral nerve damage and motor disability. Developed in collaboration with Ionis, Wainua is the only approved medicine for ATTRv-PN that can be self-administered via an auto-injector, offering patients a new level of autonomy and convenience.

Company Profile

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines. The company operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. AstraZeneca is headquartered in Cambridge, UK.

Contact details

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA


Tel: +44 (0)20 3749 5000